SLC22A12 and hyperuricemia: Genome-wide association studies (GWAS) implicate genetic variants in URAT1, OAT4, OAT10, and GLUT9 in the development of hyperuricemia9–12, suggesting the possibility that patients with hyperuricemia have gain-of-function variants of these transporters that promote the retention of uric acid.